PegBio's Weekly Diabetes Drug Added to China's 2026 Reimbursement List

MT Newswires Live11-16

PegBio (HKG:2565) said China's 2026 National Reimbursement Drug List will include its weekly diabetes treatment visepegenatide injection, marketed as Paidakang.

The drug is a long-acting GLP-1 receptor agonist approved by China's National Medical Products Administration in November 2025 for blood glucose control in adults with Type 2 diabetes, according to a Sunday Hong Kong bourse filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment